National Academies Press: OpenBook

Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction (2001)

Chapter: A Presentations and Submissions

« Previous: 16 Other Health Effects
Suggested Citation:"A Presentations and Submissions." Institute of Medicine. 2001. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: The National Academies Press. doi: 10.17226/10029.
×
Page 583
Suggested Citation:"A Presentations and Submissions." Institute of Medicine. 2001. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: The National Academies Press. doi: 10.17226/10029.
×
Page 584
Suggested Citation:"A Presentations and Submissions." Institute of Medicine. 2001. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: The National Academies Press. doi: 10.17226/10029.
×
Page 585

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

A Presentations and Submissions The committee would like to thank the following people who shared their expertise. PRESENTATIONS December 15, 1999, Washington, D.C. Presentation of the Charge to the Institute of Medicine Committee Mitch Zeller, Food and Drug Administration (current affiliation, American Legacy Foundation Bern Schwetz, Food and Drug Administration March 2, 2000, Washington, D.C. Harm Reduction and Lessons Learned: Historical Perspective and Policy Advice John Slade, University of Medicine and Dentistry at New Jersey School of Public Health Harm Reduction and Lessons Learned: Low Tar and Nicotine Story Don Shopland, National Cancer Institute Tobacco Toxicology Review: Emphasis on Carcinogenesis Steve Hecht, University of Minnesota Exposure Assays David Ashley, Centers for Disease Control and Prevention Nicotine Pharmacology and Toxicology Neal Benowitz, University of California, San Francisco 583

584 APPENDIX A April 25, 2000, Washington, D.C. Risk Perception and Decision Making Paul Slovic, Decision Research, University of Oregon Epidemiology of Low-Tar Cigarettes David Burns, University of California, San Diego Clinical Trial Design Considerations Jack Henningfield, Pinney Associates, Johns Hopkins School of Medicine Janine Pillitteri, Pinney Associates John Hughes, University of Vermont Clinical Indicators of Chronic Obstructive Pulmonary Disease Steve Rennard, University of Nebraska Physical and Chemical Characteristics of Tobacco Smoke Robert Phalen, University of California, Irvine State of Massachusetts Regulation of Tobacco Products Gregory Connolly, Massachusetts Department of Public Health Michael Borgerding, R.J. Reynolds Tobacco Company CONTRIBUTIONS Thoughtful contributions were also provided by the following: Industry Representatives Brown and Williamson Tobacco Company Scott Appleton Sharon Boyse Rufus Honeycutt Tilford Riehl Lorillard Tobacco Company Christopher Coggins and colleagues Chuck Gaworski J. Dan Heck Philip Morris Tobacco Company Richard A. Carchman Bruce D. Davies Hans-Juergen Haussmann Robin D. Kinser Donald E. Leyden George J. Patskan Richard P. Solana Anthony R. Ticker

APPENDIX A 585 R.J. Reynolds Tobacco Company Michael Borgerding J. Donald deBethizy David Doolittle David Iauco Arnold T. Mosberg Seth Moskowitz John H. Robinson Robert L. Suber James E. Swauger Star Scientific, Inc. Scott D. Ballin Jerome H. Jaffe Paul L. Perito GlaxoWellcome Pharmacutical Brenda Jamerson Pharmacia Corporation Mikael Franzon Vibeke Kronborg Smith Kline Beecham Individuals Gregory Dalack, VA Ann Arbor Healthcare System Karl Fagerstrom, Fagerstrom Consulting Nigel Gray, European Institute of Oncology Jack Henningfield, Pinney Associates Thomas Houston, American Medical Association John Hughes, University of Vermont Anne Kirchner, Food and Drug Administration Robert Nilsson, National Chemicals Inspectorate, Sweden Brad Radu, University of Alabama Elsy-Britt Schildt, University Hospital, Sweden Saul Shiffman, University of Pittsburgh and Pinney Associates John Slade, University of Medicine and Dentistry at New Jersey School of Public Health Steven Stellman, American Health Foundation David Sweanor, Smoking and Health Action Foundation, Canada Puzant Torigian Dennis Ole Wik Judy Wilkenfeld, Campaign for Tobacco Free Kids Richard Windsor, University of Alabama

Next: B Committee Biographical Sketches »
Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction Get This Book
×
Buy Hardback | $75.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Despite overwhelming evidence of tobacco's harmful effects and pressure from anti-smoking advocates, current surveys show that about one-quarter of all adults in the United States are smokers. This audience is the target for a wave of tobacco products and pharmaceuticals that claim to preserve tobacco pleasure while reducing its toxic effects.

Clearing the Smoke addresses the problems in evaluating whether such products actually do reduce the health risks of tobacco use. Within the context of regulating such products, the committee explores key questions:

  • Does the use of such products decrease exposure to harmful substances in tobacco?
  • Is decreased exposure associated with decreased harm to health?
  • Are there surrogate indicators of harm that could be measured quickly enough for regulation of these products?
  • What are the public health implications?

This book looks at the types of products that could reduce harm and reviews the available evidence for their impact on various forms of cancer and other major ailments. It also recommends approaches to governing these products and tracking their public health effects.

With an attitude of healthy skepticism, Clearing the Smoke will be important to health policy makers, public health officials, medical practitioners, manufacturers and marketers of "reduced-harm" tobacco products, and anyone trying to sort through product claims.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!